Information Provided By:
Fly News Breaks for October 11, 2016
EXEL
Oct 11, 2016 | 10:00 EDT
Stifel analyst Stephen Willey rasied Exelixis' price target to $17 and reiterated his Buy rating following the investor reception co-hosted by EXEL and partner Ipsen after yesterday's CABOSUN presentation. He believes the net effect of any immunotherapy-based regimen moving to front-line will be offset by the elimination of immunotherapy as a second-line treatment option, making cabozantinib de facto standard-of-care.
News For EXEL From the Last 2 Days
There are no results for your query EXEL